NCT02269059View on ClinicalTrials.gov

Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

April 30, 2015

Conditions
Hepatitis C
Interventions
DRUG

MK-7680

MK-7680 10 mg and 100 mg capsules

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02269059 - Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003) | Biotech Hunter | Biotech Hunter